Stroke prevention: missed opportunities

Lancet

Volumn 369, Issue 9565, 2007, Pages 904-905

  Guptha, Sunku Hemanth ^a   Shibu, Pazhvoor ^a   Owusu Agyei, Peter ^a  

^a EDITH CAVELL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CHOLESTEROL; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT;

BLOOD CLOT LYSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIA; LETTER; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 33947151976     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60444-9     Document Type: Letter

References (4)

1. Wahlgren N., Ahmed N., Dávalos A., et al., for the SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-282
2. Barber P., Zhang J., Demchuk A., Hill M., and Buchan A. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56 (2001) 1015-1020
3. Royal College of Physicians. National clinical guidelines for stroke. 2nd edn. (2004), RCP, London
4. The Lancet. Stroke-prevention better than cure. Lancet 369 (2007) 247